Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

U

University of Campania "Luigi Vanvitelli"

Status and phase

Completed
Phase 4

Conditions

Proliferative Diabetic Retinopathy

Treatments

Other: sham
Drug: Bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT01025934
IVBDRNA

Details and patient eligibility

About

The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • vitreous haemorrhage
  • tractional retinal detachment
  • active proliferative diabetic retinopathy.

Exclusion criteria

  • neovascular glaucoma
  • cataract
  • combined traction and rhegmatogenous RD

Trial design

0 participants in 3 patient groups

7 days
Active Comparator group
Treatment:
Drug: Bevacizumab
20 days
Active Comparator group
Treatment:
Drug: Bevacizumab
sham
Sham Comparator group
Treatment:
Other: sham

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems